In a post-hoc analysis of the SUMMIT trial [59], there was no statistical difference on the effect of tirzepatide on worsening HF event among patients with and without CKD, suggesting that the benefits of incretins in patients with HFpEF and obesity go beyond baseline CKD status. The gene discussed is GCG; the disease is obesity disorder.